FDA Approves Oral Suspension Form of Raltegravir
“On December 20, 2013, FDA approved a new dosage form, ISENTRESS® (raltegravir) for oral suspension, in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 4 weeks of age and older, weighing at least 3 kg to less than 20 kg. This also includes a new Instructions for Use document as part of the patient labeling.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Department of Health | Health | HIV AIDS | Infectious Diseases | Isentress | Pediatrics | Websites